Aller au contenu principal

 Articles scientifiques

Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks.

Auteurs : Kehrloesser S, Oberst S, Westerhuis W, Wendler A, Wind A, Blaauwgeers H, Burrion JB, Nagy P, Saeter G, Gustafsson E, De Paoli P, Lovey J, Lombardo C, Philip T, de Valeriola D, Docter M, Boomsma F, Saghatchian M, Svoboda M, Philip I, Monetti F, Hummel H, McVie G, Otter R, Van Harten W
Année : 2021
Journal : Mol Oncol
Volume : 15
Pages : 1277-1288

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

Auteurs : Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A
Année : 2016
Journal : Eur J Cancer
Volume : 60
Pages : 117-124

Participation of Italian Cancer Centres of the Alleanza Contro Il Cancro (ACC) in the Organisation of European Cancer Institutes (OECI) Accreditation and Designation program: a successful first national initiative.

Auteurs : Oberst S, Boomsma F, Lombardo C, Docter M, Blaauwgeers H, De Paoli P, de Valeriola D, Paradiso A, Saghatchian M
Année : 2015
Journal : Tumori
Volume : 101 Suppl 1
Pages : 0

Pioneering quality assessment in European cancer centers: a data analysis of the organization for European cancer institutes accreditation and designation program.

Auteurs : Saghatchian M, Thonon F, Boomsma F, Hummel H, Koot B, Harrison C, Rajan A, de Valeriola D, Otter R, Laranja Pontes J, Lombardo C, McGrath E, Ringborg U, Tursz T, Van Harten W
Année : 2014
Journal : J Oncol Pract
Volume : 10(5)
Pages : e342-9

Imbalance between supply and need of medical oncologists in Belgium

Auteurs : Dhondt V, Benahmed A, De Wever L, Dirix L, de Valeriola D
Année : 2013
Journal : Belgian J Medical Oncology
Volume : 7(2)
Pages : 38-45

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Auteurs : Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T
Année : 2012
Journal : Eur. J. Cancer
Volume : 48(4)
Pages : 465-74